Primary Gastric Lymphoma Market

Market Overview:

The 7 major primary gastric lymphoma markets reached a value of US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.1 Billion by 2034, exhibiting a growth rate (CAGR) of 14.03% during 2024-2034.

The primary gastric lymphoma market has been comprehensively analyzed in IMARC's new report titled "Primary Gastric Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary gastric lymphoma (PGL) is a rare type of non-Hodgkin lymphoma that originates in the stomach's lymphatic tissue. The symptoms of this ailment can be vague and may mimic those of other gastrointestinal disorders, making diagnosis challenging. Individuals suffering from the illness might experience abdominal discomfort, pain, bloating, early satiety, unexplained weight loss, nausea, vomiting, etc. Due to its nonspecific presentation, timely recognition of PGL is crucial. The diagnosis of lymphoma involves a combination of methods. Endoscopy with biopsy is a pivotal step, allowing for the collection of tissue samples for microscopic examination. This investigation aids in identifying lymphoma cells and determining their specific subtype. Physicians might also recommend imaging studies, such as CT scans or MRIs, to assess the extent of the disease and exclude the involvement of various other organs. Numerous diagnostic tests, like blood work, including complete blood counts and molecular analysis, can also be utilized in patients.

The escalating incidences of gene mutations, leading to abnormal growth of lymphatic cells within the stomach lining, are primarily driving the primary gastric lymphoma market. In addition to this, the inflating utilization of effective treatments, such as chemotherapy regimens, radiotherapy, immunotherapy, and surgery, aimed at managing the disease and preventing its progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, since they help in leveraging drugs that specifically pinpoint certain molecules involved in the proliferation and survival of lymphoma cells, is further bolstering the market growth. Apart from this, the rising usage of endoscopic procedures, which enable minimally invasive diagnosis and treatment by directly visualizing and accessing the affected area, is acting as another significant growth-inducing factor. These techniques facilitate accurate staging of the ailment as well as offer a platform for biopsy and subsequent therapeutic interventions. Additionally, the growing awareness of complementary approaches like nutritional support and integrative therapies that can enhance the overall well-being of patients who are undergoing treatment is also augmenting the market growth. Furthermore, the emergent application of personalized medicine strategies, which hold the potential to optimize treatment outcomes and minimize adverse effects, is expected to drive the primary gastric lymphoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the primary gastric lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary gastric lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary gastric lymphoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the primary gastric lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the primary gastric lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current primary gastric lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the primary gastric lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the primary gastric lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the primary gastric lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of primary gastric lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with primary gastric lymphoma across the seven major markets?
• What is the size of the primary gastric lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of primary gastric lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

Primary Gastric Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for primary gastric lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary gastric lymphoma market?
• What are the key regulatory events related to the primary gastric lymphoma market?
• What is the structure of clinical trial landscape by status related to the primary gastric lymphoma market?
• What is the structure of clinical trial landscape by phase related to the primary gastric lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the primary gastric lymphoma market?